
Organovo Holdings ONVO
Quartalsbericht 2025-Q4
hinzugefügt 11.02.2026
Organovo Holdings Langfristige Verbindlichkeiten 2011-2026 | ONVO
Langfristige Verbindlichkeiten Jährlich Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 588 K | 583 K | 807 K | 905 K | 32 K | 9 K | 30 K | 17 K | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 905 K | 9 K | 371 K |
Langfristige Verbindlichkeiten anderer Aktien in der Diagnostik & Forschung
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
23.7 M | - | -6.23 % | $ 30.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
61.1 M | $ 17.65 | 3.67 % | $ 176 M | ||
|
Agilent Technologies
A
|
3.29 B | $ 119.12 | 1.34 % | $ 36.2 B | ||
|
Medpace Holdings
MEDP
|
73.8 M | $ 433.29 | 0.69 % | $ 12.5 B | ||
|
Myriad Genetics
MYGN
|
107 M | $ 4.1 | -18.59 % | $ 380 M | ||
|
Akumin
AKU
|
527 M | - | -17.87 % | $ 25.9 M | ||
|
NeoGenomics
NEO
|
435 M | $ 8.7 | -1.81 % | $ 1.11 B | ||
|
National Research Corporation
NRC
|
39.6 M | $ 18.33 | -2.19 % | $ 410 M | ||
|
Natera
NTRA
|
124 M | $ 215.43 | 4.19 % | $ 21.2 B | ||
|
Koninklijke Philips N.V.
PHG
|
8.08 B | $ 27.15 | 2.65 % | $ 20 B | ||
|
Aspira Women's Health
AWH
|
3.49 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
134 M | - | -61.36 % | $ 2.46 M | ||
|
Personalis
PSNL
|
639 K | $ 6.04 | 8.54 % | $ 358 M | ||
|
Biocept
BIOC
|
11.3 M | - | -13.05 % | $ 7.29 M | ||
|
Soleno Therapeutics
SLNO
|
10.8 M | $ 52.93 | 0.01 % | $ 2.69 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
7.74 M | - | - | $ 562 M | ||
|
CareDx, Inc
CDNA
|
17.9 M | $ 20.85 | 0.7 % | $ 1.11 B | ||
|
Chembio Diagnostics
CEMI
|
24.8 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
16 K | - | - | $ 9.42 M | ||
|
HTG Molecular Diagnostics
HTGM
|
4.1 M | - | -20.0 % | $ 1.06 M | ||
|
Thermo Fisher Scientific
TMO
|
22.5 B | $ 475.86 | 1.96 % | $ 179 B | ||
|
Trinity Biotech plc
TRIB
|
106 M | $ 0.61 | 1.13 % | $ 61.9 M | ||
|
Co-Diagnostics
CODX
|
574 K | $ 1.61 | 1.26 % | $ 2.14 M | ||
|
Castle Biosciences
CSTL
|
2.76 M | $ 24.82 | 0.89 % | $ 689 M | ||
|
Twist Bioscience Corporation
TWST
|
4.56 M | $ 60.05 | 5.91 % | $ 3.59 B | ||
|
Global Cord Blood Corporation
CO
|
2.53 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
131 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
559 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
48.5 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
865 K | - | -11.32 % | $ 2.94 M | ||
|
Charles River Laboratories International
CRL
|
2.35 B | $ 186.57 | 0.64 % | $ 9.25 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.43 B | - | - | $ 10.7 B | ||
|
Waters Corporation
WAT
|
1.28 B | $ 351.47 | 2.54 % | $ 20.9 B | ||
|
Enzo Biochem
ENZ
|
4.6 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
981 M | - | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
2.26 M | $ 15.15 | 1.68 % | $ 458 M | ||
|
Guardant Health
GH
|
91.4 M | $ 91.39 | 2.09 % | $ 11.5 B | ||
|
Heska Corporation
HSKA
|
57.9 M | - | - | $ 1.31 B | ||
|
ICON Public Limited Company
ICLR
|
461 M | $ 124.91 | 2.96 % | $ 10.3 B | ||
|
Illumina
ILMN
|
2.04 B | $ 141.73 | 1.91 % | $ 22.5 B | ||
|
Senseonics Holdings
SENS
|
163 M | $ 5.11 | 2.2 % | $ 213 M | ||
|
Interpace Biosciences
IDXG
|
10 M | $ 2.01 | 0.1 % | $ 8.89 M | ||
|
QIAGEN N.V.
QGEN
|
1.99 B | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
1.57 M | $ 2.14 | -2.06 % | $ 4.92 M | ||
|
Lantheus Holdings
LNTH
|
225 M | $ 87.0 | 1.37 % | $ 5.87 B | ||
|
Laboratory Corporation of America Holdings
LH
|
7.82 B | $ 259.67 | 0.98 % | $ 21.6 B | ||
|
Celcuity
CELC
|
69.2 K | $ 142.15 | 0.32 % | $ 6.65 B | ||
|
Motus GI Holdings
MOTS
|
2.16 M | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
19.6 M | $ 9.28 | 0.11 % | $ 2.01 B | ||
|
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 191.61 | 0.4 % | $ 21.3 B |